|
|
|
|
|
|
|
|
|
|
|
|
|
10.06.26 - 14:06
|
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines (Business Wire)
|
|
|
Financing was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures SA, Vivo Capital, and existing investors
Proceeds will support clinical advancement of lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD)
SAN FRANCISCO--(BUSINESS WIRE)--#biotech--SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.
The financing was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures SA, Vivo Capital, and existing investors ARCH Ventur...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04.05.26 - 17:45
|
EDDING GENOR Partner Candid Therapeutics to Be Acquired by UCB (AAStocks)
|
|
|
EDDING GENOR (06998.HK) announced that Belgian pharmaceutical group Union Chimique Belge (UCB) will acquire Candid Therapeutics. Under the terms of the agreement, UCB will pay an upfront payment of USD2 billion, together with up to USD200 million in potential future milestone payments. The acquisition is expected to be completed......
|
|
|
|
|
|
|
04.05.26 - 02:03
|
Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics′ Acquisition by UCB (Business Wire)
|
|
|
LOS ANGELES, BOSTON & NEW YORK--(BUSINESS WIRE)--Two River, LLC (“Two River”) and Vida Ventures (“Vida”), both part of the Bellco Health ecosystem, today acknowledged the announced acquisition of Candid Therapeutics (“Candid”), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), by UCB (Euronext: UCB), a global biopharmaceutical company, for up to $2.2 billion, including $2.0 billion upfront.
Two River and Vida played central roles in the creation and early development of Candid. Two River, together with Third Rock Ventures, helped found Candid, continuing Two River's consistent track record of founding and scaling innovative biotechnology companies as a leading incubator. Candid was formed through the merger of TRC 2004—founded by Two River—and Vignette Bio, bringing together complementary capabilities with an experienced management team to establish a leader in autoimmune TCE therapi...
|
|
|
|
|
03.05.26 - 19:15
|
UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers (Business Wire)
|
|
|
Deal builds upon UCB's position as a leader in immunology innovation and expands capabilities in next-generation biologics with potential for immune reset
Candid's lead asset, cizutamig, a bispecific antibody directed to B-cell maturation antigen (BCMA) on plasma cells and CD3 on T-cells, is currently in multiple phase 1 clinical studies across various autoimmune diseases
Total transaction value of up to US $2.2 billion consisting of US $2 billion in upfront payments plus up to US $200 million in potential future milestone payments
SAN DIEGO--(BUSINESS WIRE)--UCB, a global biopharmaceutical company, today announced signing of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs). This transaction supports UCB's ambition to bring differentiated solutions to people with severe immune-mediated diseases by focusing on areas o...
|
|
|
29.04.26 - 23:57
|
XETR: DIVIDEND/INTEREST INFORMATION - 04.05.2026 - BE0003739530 (XETRA)
|
|
|
Das Instrument UNC BE0003739530 UCB S.A. EQUITY wird cum Dividende/Zinsen gehandelt am 30.04.2026 und ex Dividende/Zinsen am 04.05.2026
The instrument UNC BE0003739530 UCB S.A. EQUITY has its pre-dividend/interest day on 30.04.2026 and its ex-dividend/interest day on 04.05.2026...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
